"We need telehealth the way we had it for COVID," Cathie Biga told Cardiovascular Business at TCT 2025. "We don't want to go back to having it so restricted."
Adults are three times as likely to have a heart attack or stroke after a COVID-19 infection than when they are healthy. The risks are even greater for the flu.
Bleeding events remain a serious complication after TAVR. By identifying high-risk patients early and planning ahead, however, care teams can keep them to a minimum.
Pfizer was all set to acquire New York City-based Metsera for $4.9 billion, but Novo Nordisk stepped in with an unexpected counteroffer of $6.5 billion. Both companies hope to add Metsera's drugs to their GLP-1 portfolios.
B. Hadley Wilson, MD, talked to Cardiovascular Business about several standout late-breaking clinical trials presented at TCT 2025. Topics of those trials included drug-coated balloons, TAVR valve durability, pulmonary embolism treatments and much more.
New data on the RDN systems from Recor Medical and Medtronic confirmed that this relatively new technology brings long-term relief to patients with uncontrolled hypertension.
Adam Greenbaum, MD, explains how transcatheter electrosurgery can be used to prevent left ventricular outflow tract (LVOT) obstruction using a new procedure called Septal Scoring Along the Midline Endocardium (SESAME).
Researchers recently used advanced 4D flow MRI to track blood in a pulsating artificial heart, revealing dynamics that closely mirror those of a healthy human organ.
Congress needs to act soon to extend telemedicine services that were greatly expanded under COVID provisions, or they will expire by October. Anders Gilberg, senior vice president of government affairs at the Medical Group Management Association, explains concerns raised by doctors and lawmakers.
Anders Gilberg, senior vice president of government affairs at the Medical Group Management Association, explains the political and patient care issues involved with ending Affordable Care Act subsidies.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/stack_views/public/2024-09/istock-1209664264.jpg.webp?itok=MzQCOefT)
